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Abstract
It is increasingly common clinically for cancer specimens to be examined using techniques
that identify somatic mutations. In principle these mutational profiles can be used to diagnose
the tissue of origin, a critical task for the 3-5% of tumors that have an unknown primary
site. Diagnosis of primary site is also critical for screening tests that employ circulating DNA.
However, most mutations observed in any new tumor are very rarely occurring mutations, and
indeed the preponderance of these may never have been observed in any previous recorded tumor.
To create a viable diagnostic tool we need to harness the information content in this hidden
genome of variants for which no direct information is available. To accomplish this we propose
a multi-level meta-feature regression to extract the critical information from rare variants in
the training data in a way that permits us to also extract diagnostic information from any
previously unobserved variants in the new tumor sample. A scalable implementation of the
model is obtained by combining a high-dimensional feature screening approach with a group-lasso
penalized maximum likelihood approach based on an equivalent mixed-effect representation of the
multilevel model. We apply the method to the Cancer Genome Atlas whole-exome sequencing
data set including 3702 tumor samples across 7 common cancer sites. Results show that our
multi-level approach can harness substantial diagnostic information from the hidden genome.
Key-words and Phrases: Cancer classification; Group-lasso penalty; Multi-level models; Multi-
nomial logistic regression; Whole-exome mutations.
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1 Introduction
Identifying the anatomic site of origin of malignancy is a crucial problem in cancer diagnosis,
including cancers of unknown primary which make up 35% of total cancer diagnoses worldwide
and are associated with poor prognosis (Varadhachary and Raber, 2014; Conway et al., 2018), as
well as in the more recent context of “liquid biopsies” whereby circulating tumor DNA (ctDNA)
is identified in the blood and can in principle be used for early detection of cancer (Diaz Jr and
Bardelli, 2014; Wan et al., 2017). In recent years, large-scale sequencing studies have begun to
reveal the somatic mutational landscape in cancer. Evidence emerging from these studies suggests
that common somatic mutations can be highly organ site specific (Haigis et al., 2019). This serves
as a basis for identifying site of origin using the mutational profile identified from the tumor sample
or from ctDNA sequencing.
Predicting cancer types based on mutations, however, comes with its own sets of challenges.
Advances in modern genome sequencing technologies and their application to large cancer patient
cohorts have resulted in the discovery of millions of unique somatic mutations (variants) in the
tumor genome. It is well known that a relatively small number of variants appear in tumors
frequently, but the vast majority of variants occur extremely infrequently. Data from large-scale
sequencing studies such as the Cancer Genome Atlas (TCGA, Bailey et al., 2018) revealed that over
90% of the somatic variants in the study were singletons, i.e. observed only once in the >10,000
sequenced tumor samples. The vast trove of these extremely rare variants, routinely ignored or
under-utilized, may in fact harbor important signals that can be harnessed for clinically relevant
problems. A statistical and computational solution to extract relevant information from these rare
variants is needed.
Furthermore, there are many more variants yet to be discovered, and virtually every gene
sequencing experiment identifies a multitude of previously unseen mutations. This makes variant-
based prediction of cancer types extremely difficult: in sequencing of a new tumor, for many (if not
all) mutations in the tumor there will be little or no direct previous information. One approach
is to perform classification only at the gene level (Soh et al., 2017). That is, instead of using
the individual variants directly, the genes in which the mutations occurred are used as predictors.
This strategy aggregates all (including rare) variants in a gene and reduces the total dimension of
predictors, as the total number of genes is much smaller than the total number of possible variants.
Furthermore, all genes are known, and hence the problem of encountering predictors that were not
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present in the training data does not arise. However, this approach ignores variant-level information
that can be critical. For example, common variants in the KRAS gene are known to be highly
tissue-specific: the KRAS G12C variant is primarily associated with lung adenocarcinoma, while
KRAS G12R occurs more exclusively in pancreatic cancers. Thus, a gene level classification model
is likely to produce sub-optimal results as such variant-level discriminant information is lost.
We note that the problem of tumor classification based on mutation profiles has analogies with
content-based text classification problems in natural language processing. The work of Taskar
et al. (2003) is particularly noteworthy in this context. The authors suggest “learning” the role
of a previously unseen word (feature) through its context, i.e., neighboring words/features, while
classifying a new text document. In the field of machine learning in general the problem of classifi-
cation/prediction with previously unseen features can be framed as a problem of domain adaptation
or transfer learning (Shi and Knoblock, 2017), where a model trained on a specific source domain
is adapted to a related but different target domain. Existing approaches to domain adaptation
problems include tree based ensemble methods (Habrard et al., 2013), nearest neighbor regres-
sion/classification techniques (Shi and Knoblock, 2017), and neural networks (Ganin et al., 2016).
However, as is often the case in the machine learning literature, many of these approaches are
black-boxes, and do not aid interpretable statistical inference on the model parameters (and thus
on the predictors).
The major contribution of this paper lies in the development of a rigorous statistical framework
that through the associated DNA sequence context infers the effects of previously unseen variants
and subsequently uses these inferred effects in the prediction of cancer sites. More precisely, we
build a multi-level classification model with an embedded hierarchical meta-regression step in which
the effects of all (including previously unseen) variants are modeled as functions of a number of
known meta-features describing the associated mutation contexts. Through the meta-regression,
these meta-features can be used to quantify the effects of previously unseen variants in a new tumor,
and simultaneously provide a highly informative yet substantially smaller dimensional projection
of the ultra high-dimensional (in the order of millions) predictor space. In our example we employ
two categorical meta-features, the gene itself and the single base substitution membership of the
variant, though the model can easily be extended to include other meta-features.
Through an equivalent mixed-effect representation of our multi-level model, we demonstrate
how these meta-features affect classification. In particular we note how our approach rigorously
combines information from the raw variants as well as from the genes in which the variants originate,
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thus providing a refinement and extension to the existing gene-level approaches (Soh et al., 2017).
Careful assignment of a shrinkage prior as a further hierarchical layer in the mixed effect model
aids a group-lasso regularized likelihood of the model parameters of interest, thus enabling straight-
forward implementation. The parameter estimation is performed following a mutual information-
based feature screening (Cover and Thomas, 2012a). This makes our approach highly scalable,
allowing incorporation of possibly millions of variants and appropriately chosen meta-features. We
apply the method to the publicly available TCGA mutation data set, electing to focus on 7 common
cancer types.
The remainder of the article is organized as follows. In Section 2, we provide a brief description
of the TCGA data. In Section 3 we first provide some intuition on our variant and meta-information
based approach, then formalize the intuition in terms of a (sparse) multi-level multinomial logistic
classification model, and finally describe an implementation strategy for our model that can handle
millions of variants as predictors. Section 4 describes the application of our model to the TCGA
data set. Finally, in Section 5 we address strengths and limitations of our method, and research
directions that will be pursued in future. Additional technical and numerical details are included
in the Appendix.
2 Data source and description
The somatic variant data are from the Cancer Genome Atlas (TCGA) study derived from whole-
exome sequencing of approximately 10,000 tumor samples across multiple cancer types (Bailey et al.,
2018). We focus our attention on the 7 most prevalent tumor types (as determined by the SEER
(Duggan et al., 2016) program of the National Cancer Institute), namely bladder urothelial carci-
noma (BLCA), breast invasive carcinoma (BRCA), colorectal adenocarcinoma (COADREAD), lung
adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD),
and skin cutaneous melanoma (SKCM). These have sample sizes (number of tumors) of 411, 1025,
559, 568, 176, 495, and 468 respectively. Among these 3702 tumors a total of 811,497 unique so-
matic variants were identified, the majority of which were rare variants (see Table 2). Specifically,
95% of all observed variants are singletons (appearing only once in the cohort).
A key challenge involves making use of new variants emerging in a future tumor sample that
have not been observed in the training cohort. In earlier work we showed that 60% of mutations
identified in new tumors are expected to be variants not observed in the TCGA cohort (Chakraborty
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r 1 2 3 4 5 6 7 8 9 10
0+ 770057 35027 4541 1077 384 175 77 40 28 19
10+ 11 7 4 2 4 3 5 2 1 2
20+ 2 1 4 1 0 0 0 0 2 0
30+ 1 2 1 2 1 0 1 0 0 1
40+ 0 0 0 0 0 1 0 1 0 1
50+ 0 0 0 0 0 0 0 0 0 0
60+ 0 1 0 0 0 0 0 0 0 0
...
...
...
...
...
...
...
...
...
...
...
260+ 0 0 1 0 0 0 0 0 0 0
Table 1: Out of the 811,497 unique variants observed in the 3702 TCGA tumors with one of the
seven cancer types, the number of variants Nr that appear exactly r times (i.e., in r tumors),
r = 1, 2, . . . , 270, are displayed for various r’s. The (i, j)-th cell shows the observed value of Nr
corresponding to r = 10(i − 1) (= left row border) +j (= top column border). For example, the
(1, 1)-th entry, 770057, is the observed value of N0+1 = N1, the number of singletons. The (4, 3)-th
entry, 1, tells us that there was a single variant observed 33 times.
et al., 2019).
3 Multi-level model for cancer type prediction
3.1 Notation and intuition
Consider a training data set consisting of mutation profiles of m tumors with known cancer types
and a test data set of n −m (n > m) tumors whose cancer types we aim to predict. For the i-th
tumor the associated true cancer label is ci ∈ {1, . . . ,K}, where K is the number of candidate
cancer types. We call variants that have been observed at least once in the training cohort as
“recorded” variants, and we have information on the presence/absence of d1 such recorded variants
in the training set. Let xij denote the binary indicator of the presence/absence of the j-th variant
in i-th individual (0 = absence, 1 = presence), j = 1, . . . , d1. In the test set, we seek to predict
the cancer labels based on information on the presence/absence of d = d1 + d2 variants in total,
where d2 denotes the number of variants in the test data that do not occur in the training data. A
diagrammatic representation of the problem is provided in Figure 1.
We consider a multinomial logistic (“softmax”) regression framework for this classification prob-
lem, where for k = 1, . . . ,K, the probability P (ci = k) of the i-th tumor having cancer type k is
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...
Tumor 1
Mutation profile: 
𝒙1 = 𝑥1𝑗
Cancer site: 𝑐1
Tumor 𝑚
Mutation profile: 
𝒙𝑚 = 𝑥𝑚𝑗
Cancer site: 𝑐𝑚
…
Training Set
...
Tumor 𝑚 + 1
Mutation profile: 
𝒙𝑚+1 = 𝑥𝑚+1,𝑗
Cancer site: ??
Tumor 𝑛
Mutation profile: 
𝒙𝑛 = 𝑥𝑛𝑗
Cancer site: ??
…
Test Set
Variants 1,… , 𝑑1 observed at least once
Presence/absence of 𝑑1training set variants &
𝑑2 previously unseen variants 𝑑1 + 1,… , 𝑑 = 𝑑1 + 𝑑2
Figure 1: Diagrammatic representation of the mutation profile based tumor site classification prob-
lem.
modeled as the softmax (normalized exponential) of linear functions of the predictors xij ’s (see Sec-
tion 3.2). A recorded-variant-only approach fits a classification model to the training data using the
raw variants observed in that data set as predictors, and predicts cancer types of test set mutations
based on that fitted model. Clearly, this approach can only utilize the information provided by the
training set recorded variants, and fails to make use for classification purposes of any information
in the multitude of mutations observed only in the test data set.
We have developed a multi-level meta-feature regression framework to properly employ of the
information in those new (observed only in the test set) variants while classifying the cancer type
of a new tumor. To this end, we first make a key observation: irrespective of whether a variant is
“recorded” or “new”, we always have some quantifiable information obtained from the associated
DNA sequencing contexts, called meta-features in this paper. The key idea then involves inferring
the effects of new variants from those of the recorded variants with similar meta-features. In terms
of a multinomial logistic model, this amounts to connecting the logistic regression coefficients for
variants to these meta-features through an appropriate hierarchical meta-regression step. Using
this hierarchical meta-regression, the regression coefficients for the new variants in a tumor outside
the training set can then be “predicted”, and subsequently used for classification. The following
section formalizes this idea via an appropriate multilevel model.
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3.2 Model
Let us denote by uj = (uj,1, . . . , uj,p)
T the values of p meta-features associated with the variants,
j = 1, . . . , d = d1+d2. Recall that only the first d1 variants are observed in the training data, i.e., the
first m of the n total tumors. In this study we include two categorical meta-features on each variant:
the nucleotide substitution signature associated with each variant, and gene membership, and we
dummy code each category. More precisely, we define p binary meta-features of which the first
96 indicate whether a variant corresponds to one of 96 possible single base substitution signature
categories (see Section 4.1 for more details), and the remaining meta-features are indicators of
∼ 600 OncoKB cancer genes (Chakravarty et al., 2017). We define the design matrix X ∈ Rn×d
as XT = (x1, . . . ,xn), where xi = (xi1, . . . , xid)
T , i = 1, . . . , n. (Note that while training we only
have access to xi1, . . . , xid1 , for i = 1, . . . ,m; the regression parameters associated with the new
variants d1 + 1, . . . , d are not identifiable in the training data set, and hence not estimated.) Also,
let U ∈ Rd×p be the meta-design matrix defined as UT = (u1, . . . ,ud). This unified representation
with all tumors (training and test combined) and all variants (both recorded and new) simplifies
notation and enables development of a multi-level classification model as described in the following.
The multi-level multinomial logistic regression model is defined as follows:
P (ci = k) =
exp
[
αk +
∑d
j=1 xijβj,k
]
∑K
k′=1 exp
[
αk′ +
∑d
j=1 xijβj,k′
] , independently for i = 1, . . . , n; k = 1, . . . ,K
βj,k ∼ N(uTj ω•,k, τ2j ), independently for j = 1, . . . , d; k = 1, . . . ,K
ωl,k ∼ N(0, ξ2l ), independently for l = 1, . . . , p; k = 1, . . . ,K (1)
where α = (α1, . . . , αK)
T ∈ RK×1 is the vector of intercepts; β = (βj,k) ∈ Rd×K is the matrix of
individual variant regression coefficients with k-th column being β•,k = (β1,k, . . . , βd,k)T ∈ Rd×1,
k = 1, . . . ,K and the j-th row being βj,• = (βj,1, . . . , βj,K) ∈ R1×K , j = 1, . . . , d; ω = (ωl,k) ∈ Rp×K
is the matrix of meta-regression coefficients, listing the coefficients associated with each meta-feature
for various cancer types, with the l-th row of ω being ωl,•, l = 1, . . . , p, and the k-th column being
ω•,k, k = 1, . . . ,K.
The second level in (1) encapsulates the key meta-feature regression step in our multi-level
model. This step aids estimation of the meta-feature effects ω•,k through the recorded variants.
These estimated meta-feature effects ωˆ•,k can subsequently “predict” the regression effects {βj,k}
for a new variant j (j > d1) as βˆj,k = u
T
j ωˆ•,k. Note that because we only have access to the first
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m tumors and the first d1 variants in the training data, the regression effects {βd1+1,k, . . . , βd,k}
for new variants are not identifiable and hence cannot be estimated in the training data set (only
{β1,k, . . . , βd1,k} can be estimated from the training data). A prediction of the cancer label ci for
a test set individual i (i = m+ 1, . . . , n) is made using βj,k’s estimated from the training data for
j ≤ d1, and the βj,k’s predicted via the meta-feature regression for j > d1.
Furthermore, this meta-feature regression step also aids a substantial dimension reduction of
the predictor space. This becomes clearer in an alternative mixed-effect representation of the model
described in the following section. This mixed-effect representation, in addition to aiding dimension
reduction, also provides interpretation of the model parameters and aids scalable implementation.
3.3 Alternative mixed-effect representation
Instead of estimating the model parameters in (1) directly, we first rewrite the model using a
mixed-effects representation of β, and then note how this alternative representation substantially
simplifies implementation. Note that the second level in (1) can be expressed as
βj,k = β
0
j,k + u
T
j ω•,k (2)
where β0j,k ∼ N(0, τ2j ). Writing
∑d
j=1 xijβ
0
j,k = x
T
i β
0
•,k, where β
0
•,k = (β
0
1,k, . . . ,β
0
d,k) and
∑d
j=1 xijuj =
xTi U , we obtain the following alternative representation of (1):
P (ci = k) =
exp
[
αk + x
T
i β
0
•,k + x
T
i Uω•,k
]
∑K
k′=1 exp
[
αk′ + x
T
i β
0
•,k′ + x
T
i Uω•,k′
] , i = 1, . . . , n; k = 1, . . . ,K
β0j,k ∼ N(0, τ2j ), j = 1, . . . , d; k = 1, . . . ,K
ωl,k ∼ N(0, ξ2l ), l = 1, . . . , p; k = 1, . . . ,K. (3)
From representation (3), it follows that the penalized likelihood/un-normalized (i.e., without the
normalizing constant) posterior density of α, β0 = (β0j,k) and ω is essentially that of a regular-
ized multinomial logistic regression likelihood with intercept α, predictors (xTi ,x
T
i U), associated
regression coefficients β0 and ω, and with ridge penalties on β0 and ω. For a fixed j (l), the as-
sumption of equal variance of β0j,k (ωl,k) for all k aids shrinkage/partial pooling in the estimation of
the associated residual-regression (meta-regression) parameters, as is typical in multilevel models.
The following observations are made as consequences of the reparameterization (3). First,
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through xTi U , the meta-features are now directly “connected” to the classification (first level of
the model). Note that, for a meta-feature l, xTi U•,l quantifies the total mutational information or
the total mutation burden in tumor i that is described by that meta-feature, where U•,l denotes
the l-th column of the meta-design matrix U . For example, if U•,l corresponds to the dummy
variable indicating whether or not the variants are mutations at a specific gene Gl, (i.e., uj,l = 1
if the j-th variant is indeed mutation of gene Gl, and 0 otherwise) then x
T
i U•,l counts the total
number of mutations at gene Gl observed in tumor i. Consequently, the meta-regression parameter
ωl,k measures the effect of gene Gl in describing the cancer type k of a tumor. Note that this
“connection” naturally combines the effects of the individual variants and those of the genes where
a mutation occurred, thus providing a refinement of the existing gene-based classification approach.
Second, owing to the decomposition (2), β0j,k can be viewed as the j-th variant specific residual effect
that is not explained by the meta-regression. As is the case in any mixed effects model, these variant
specific residual effects can only be measured for a variant that is present in the training data set,
i.e., for j ≤ d1. (Indeed it can only be realistically utilized for the relatively few variants that occur
somewhat frequently.) For j > d1, the predicted residual effects β
0
j,k are all zero. Third, observe
that associated with each tumor i, xTi U essentially combines the presence/absence information of
all training set/recorded variants through the meta-features; the condensed information is then used
in classification. In other words, the product design-meta-design matrix XU obtained by stacking
the rows xTi U , i = 1, . . . ,m, aids a natural and potentially highly informative lower dimensional
projection of the raw variant design matrix X. Once information from all variants are properly
condensed in the product design-meta-design matrix XU , the less informative variants can then be
screened out from the design matrix X using an appropriate feature screening technique, such as an
information-theory based feature screening method (Brown et al., 2012) and/or sure independence
screening (Fan and Lv, 2008, 2017).
3.4 Group Lasso Formulation for Parameter Estimation
Note that the primary parameters of interest in model (3) (and (1)) are α, β0, and ω (and hence
β), and the remaining are nuisance hyper-parameters. We propose estimation of the primary
parameters through their marginal posterior modes (i.e., marginal a posteriori estimates). To this
end, we include one additional hierarchical layer specifying the same gamma prior distributions
on {τ2j } and {ξ2l }, and then marginalize out {τ2j } and {ξ2l } from the posterior density to obtain
a group-lasso (Kyung et al., 2010; Yuan and Lin, 2006) regularized multinomial logistic likelihood
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for α, β0 and ω. In particular, we consider
τ2j , ξ
2
l ∼ independent Gamma((K + 1)/2, λ2/2), j = 1, . . . , d, l = 1, . . . , p
Then marginalizing out {τ2j } and {ξ2l } from the joint posterior density yields the following group-
lasso regularized multinomial logistic log-likelihood for α, β0 and ω:
log pi(α,β0,ω | λ, c1, . . . , cn,x1, . . . ,xn)
=
n∑
i=1
K∑
k=1
1(ci = k) log
 exp
[
αk + x
T
i β
0
•,k + x
T
i Uω•,k
]
∑K
k′=1 exp
[
αk′ + x
T
i β
0
•,k′ + x
T
i Uω•,k′
]

− λ
d∑
j=1
‖β0j,•‖2 − λ
p∑
l=1
‖ωl,•‖2 (4)
where ‖ · ‖2 denotes the squared norm, defined for v = (v1, . . . , vK) as ‖v‖2 = (
∑K
k=1 v
2
k)
1/2.
Maximizing (4) yields the group-lasso maximum marginal a posteriori estimates of α, β0 and ω
(and hence of β). An important consequence of assigning a group lasso penalty is that for any
j (or any l), the maximum marginal a posteriori estimates of {β0j,1, . . . , β0j,K} (or {ωl,1, . . . , ωl,K})
are either all exactly zero or all non-zero. In other words, the model aids variable selection at
a collective variant and/or meta-feature level, i.e., either all cancer site-specific effects associated
with a single variant and/or a single meta-feature are retained in the fitted model, or they are all
dropped.
3.5 Prediction of Cancer Sites for New Tumors
Given the estimated residual regression parameters βˆ0j,•, j = 1, . . . , d1, intercepts αˆ, and meta-
regression parameters ωˆl,•, l = 1, . . . , p, and the test data meta-design matrix U , the cancer
site prediction (classification) of a test set tumor i with variant indicators xi = (xi1, . . . , xid)
is performed as follows. First we set βˆ0j,• = 0 for all j = d1 + 1, . . . , d, and obtain the full
residual regression coefficient matrix βˆ0 = ((βˆ0j,k : j = 1, . . . , d, k = 1, . . . ,K)). Then for each k,
we compute ηˆi,k = αˆk + x
T
i βˆ
0
•,k + x
T
i Uωˆ•,k, and subsequently normalize exp(ηˆi,k) to obtain the
predicted probability of the tumor i being of cancer type k: Pˆ (ci = k) = exp(ηˆi,k)/
∑K
k′=1 exp(ηˆi,k′).
These probabilities provide a soft classification for tumor i; a hard classification can be obtained
by assigning tumor i to class k∗ = arg maxk=1,...,K Pˆ (ci = k). It is of note that since the residual
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effects {β0j,k} are all zero for a new variant j ≥ d1 + 1, the contribution of such a variant in ηˆi,k
comes only through the j-th term of the sum xTi Uωˆ•,k, namely, xiju
T
j ωˆ•,k, which is the “predicted”
(through the meta-regression) effect of the variant j, multiplied by the binary indicator xij of that
new variant being present in the i-th individual. That is, given a new variant in a new tumor, we
first predict the effect of that new variant based on its meta features and then use the predicted
effect in classification.
Remark 3.1 From representation (3) it follows that our model essentially builds a classifier with
two sets of predictors: the variant indicators xi and the total mutation burden described by the
meta-features xTi U (e.g., total number of mutations at each gene, and the total number of mutations
associated with each single nucleotide change) in tumor i.
Remark 3.2 It is of note that the symmetric representation of the multinomial logistic model pro-
vided in the first level of (3) (or (1)) does not identify the intercept and regression parameters by
itself. For any values of the parameters {αk,β0•,k,ω•,k}k=1,...,K , {αk − γ,β0•,k − γ,ω•,k − γ}k=1,...,K
provide the same multinomial probabilities for any γ ∈ (−∞,∞). However, the (prior) distribu-
tions specified in the second and third levels of (1) identify these parameters, and hence aid their
estimability. See, e.g., Zhu and Hastie (2004) and Friedman et al. (2010) for more details.
Remark 3.3 The symmetric representations of the multinomial logistic regression provided in the
first levels of (3) and (1) do not aid direct interpretation in terms of the predictors in the model.
To achieve a log-odds ratio interpretation of the regression/meta-regression parameters, one first
needs to define a reference category (say 1). Then βj,k − βj,1 (or ωj,k −ωj,1) measures the resulting
change in the log odds of the cancer type being k relative to being type 1, when the j-th variant
status is changed from absent to present, while keeping the statuses of all other variants fixed (or
the total mutational burden captured through l-th meta-feature is changed by one unit, while keeping
mutation burden described by other meta-features fixed). The residual effect parameters {β0j,k} in
(3) are interpreted as effects of variant j that are not explained by the meta-feature regression.
Formally, β0j,k − β0j,1 measures the unexplained/residual change in the log odds of the cancer type
being k relative to being type 1 after accounting for the “expected” change as “predicted” through
the meta-feature regression (viz., uTj (ω•,k − ω•,1)), when the j-th variant status is changed from
being absent to being present, while keeping the statuses of all other variants fixed.
Remark 3.4 It is to be noted that that the penalty parameter λ in (4) weights all regression pa-
rameters equally. Hence, the predictors xi and x
T
i U should all be scaled prior to fitting the model
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(Tibshirani, 1997). For a given λ, the penalized likelihood (4) can be efficiently optimized using a
cyclical coordinate descent algorithm as described in Friedman et al. (2007) and Friedman et al.
(2010). This approach is highly scalable, and can handle thousands of predictors (variants and meta
features combined). The penalty parameter λ can be chosen via a model-selection procedure such as
cross-validation. The R package glmnet (Simon et al., 2011) provides an efficient implementation
of this optimization approach, along with a cross-validation based selection of the penalty parameter.
4 Data application: predicting cancer site of origin of TCGA tu-
mors
We implemented our multi-level classification model using data from TCGA of the 7 highest preva-
lence tumor types, as determined by the SEER program of the National Cancer Institute (Duggan
et al., 2016).
4.1 Classification performance under cross-validation
We conducted five-fold cross-validation to assess the prediction performance of our method. The
entire set of 3702 tumors was partitioned into five random folds (maintaining the relative propor-
tions of the seven cancer types as observed in the full data). Four out of the five folds were treated
as the training set, and the fifth fold was treated as the test set in which the cancer site labels were
masked, and all five combinations of test and training sets were considered for a given partition.
The predicted class probabilities in the test sets were subsequently compared with the actual labels
to evaluate prediction accuracy.
To fit our model, we first obtained xij , the presence/absence indicator of variant j in the i-th
tumor in the training set, for all whole-exome variants that were observed at least once in the
training data. (On a typical training set there were around 620,000 variants appearing at least
once on average.) The meta-features involved dummy coded presence/absence indicators of the
584 clinically relevant cancer genes constituting the oncoKB list (Chakravarty et al., 2017) and the
96 single base nucleotide substitution signatures. The single base nucleotide substitution signature
is the type of alteration (e.g., C to T transitions) in the trinucleotide context. For each mutated
locus, there are six classes of base substitution (C¿A, C¿G, C¿T, T¿A, T¿C, T¿G), together with
the nucleotide base immediately 5’ and 3’ to each mutated base, yielding a total of 96 possible single
base nucleotide substitution signature types. These alterations are the key elements in classical
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mutation signature analysis (Alexandrov et al., 2013), and reveal the mutagenic processes specific
to certain cancer types (e.g., the C¿T and C¿G mutations at TpCpN trinucleotides are signature
of APOBEC defect which is prevalent in bladder cancer). The design matrix X = ((xij)) and the
product design-meta-design matrix XU were subsequently obtained. As described in Section 3.3,
the (i, l)-th element of the product design-meta-design matrix XU is the total burden in the
i-th tumor that is associated with the l-th meta feature (a specific gene or corresponding to a
specific neucleotide change signature), and thus can be computed without actually constructing
the meta-design matrix U and performing the computationally expensive high dimensional matrix
multiplication of X and U .
After obtaining X and XU , we performed a screening of the raw variants to find and retain the
most discriminating ones in the sparse multilevel multinomial logistic model. For this, we used a
normalized mutual information (NMI) based feature screening (Strehl and Ghosh, 2003; Cover and
Thomas, 2012b) which can be regarded as a generalization of the feature importance based sure
independence screening approach described in Fan and Lv (2008). See Web Appendix A for the
definition and a brief note on normalized mutual information. We estimated the NMI with cancer
types separately for all variants in the training data, and filtered out from the design matrix X all
variants with NMI ranking ≥ 250.
Along with our multi-level model with observed variants as predictors, and the associated gene
labels and mutation footprints as meta-features, we also considered the following three competing
models to compare their relative classification performances: (a) a group-lasso penalized sparse
multinomial logistic classifier with the predictors being indicators of the presence/absence of mu-
tations at each of the 584 oncoKB genes, (b) a random forest gene level classifier with the same
predictors as in (a), and (c) a recorded-variant-only sparse multinomial logistic classifier with group
lasso penalty. Thus (a) tells us the achievable accuracy, based on a generalized linear model, using
only gene-level information; (b) is a non-parametric version of (a) with the generalized linear and
parametric assumptions removed (and thus has a potentially better predictive ability than (a)),
and (c) tells us the extent of diagnostic accuracy using only recorded variant specific information.
For (c), we first performed a similar feature screening as done in our multilevel model, but kept
all variants with NMI ranking < 1000. All group lasso penalty parameters were chosen via sepa-
rate (independent) 10 fold cross-validations. All computations were done in statistical software R v
3.4.4 (R Core Team, 2018), and the packages tidyverse (Wickham, 2017), data.table (Dowle and
Srinivasan, 2019), Matrix (Bates and Maechler, 2019), glmnet (Simon et al., 2011), and precrec
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(Saito and Rehmsmeier, 2017) were used.
After fitting the four models on each training data set, the predicted probabilities of being
classified into each of the seven cancer types were computed for each tumor in the associated test
set for each method. These predicted probabilities were subsequently combined from all five folds.
We repeated the entire cross-validation experiment (with all four models) on 100 different random
partitions (folds) of the tumors, and then collected from each cross-validation the classification
probabilities from all four models, and in each of the seven cancer categories.
To compare predictive performances of the four competing models we considered the resulting
one-vs-rest comparison in each cancer category based on the classification probabilities. On each
cross-validation, for each method, in each one-vs-rest comparison, we obtained a precision-recall
curve by computing the precision (also called positive predictive value) and recall (also sensitivity)
associated with varying binary classification thresholds (Saito and Rehmsmeier, 2017). It is of note
that precision-recall curves are substantially more informative than receiver-operator characteristic
(ROC) curves in a classification problem with imbalanced classes, which is the case here due to the
small sample size of the PAAD class (176, 4.76% of 3702). The corresponding area under the curve
(AUC) was computed as a summary of each one-vs-rest classification performance, and the average
AUCs from all seven one-vs-rest classifications were subsequently obtained as univariate measures
of overall classification performance for each classifier. The means and the standard deviations of
these AUCs (and the overall average AUC) across all cross-validations were computed to quantify
the variability of these measures across cross-validations. These values are shown in Table 4.1.
(The actual precision-recall curves are shown in Web Figure 1).
For each of the four classifiers, a hard classification rule was obtained by assigning each tumor
to the class with highest probability. The precision-recall values for these hard classifiers were
computed under cross validations, and results are shown in Web Table 1 in Web Appendix C.
These results show a broadly similar pattern in terms of relative performances of the four methods.
From the cross validation results displayed in Table 4.1, and also Web Figure 1 and Web Table
1, it is clear that the multilevel model consistently, and often substantially, outperforms the other
three classifiers in each one-vs-rest comparison as quantified through the AUCs of the precision-
recall curves and the curves themselves, Web Figure 1. In terms of the improvement in AUC
over its closest competitor, the largest gains are observed in the cancer categories LUAD, BLCA,
SKCM and COADREAD; in the remaining three cancer types, PAAD, BRCA and PRAD, there
are still noticeable positive gains, although not as dramatic as the former three. [None of four
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Seen+Unseen
variants SMML
Gene
RF
Gene
SML
Recorded
variants SML
BLCA 0.72 (0.01) 0.64 (0.011) 0.62 (0.012) 0.51 (0.0097)
BRCA 0.72 (0.0077) 0.67 (0.0041) 0.72 (0.0057) 0.59 (0.0053)
COADREAD 0.81 (0.0078) 0.73 (0.0038) 0.75 (0.0061) 0.70 (0.009)
LUAD 0.84 (0.0028) 0.61 (0.0088) 0.63 (0.0088) 0.45 (0.0079)
PAAD 0.56 (0.014) 0.54 (0.0073) 0.52 (0.016) 0.44 (0.013)
PRAD 0.53 (0.01) 0.45 (0.01) 0.51 (0.0075) 0.26 (0.0071)
SKCM 0.94 (0.0039) 0.79 (0.0036) 0.84 (0.006) 0.84 (0.0097)
Average 0.74 (0.006) 0.63 (0.003) 0.66 (0.0085) 0.54 (0.0084)
Table 2: Area under the precision-recall curve for each one-vs-rest classification (first seven rows)
and their average (last row) obtained from the classification probabilities assigned by each classifier.
The numbers inside a cell (outside the parentheses) represents the cross-validation mean of the area
under the curves (AUCs) for the associated one-vs-rest classification (first seven rows, labeled at the
left border), or the cross-validation mean of the average AUC (from all one-vs-rest classification,
last row) for the corresponding classifier (labeled at the top border), and the numbers inside the
parentheses are the corresponding (cross-validation) standard deviations.
classifiers performs well in the cancer category PRAD, which is not unexpected, as PRAD is not a
very mutation driven cancer.] This illustrates the importance of the mutation signatures as meta-
features in our classification model (discussed in more detail in the next section). The gene-level
classifiers (random forest and sparse multinomial logistic) have similar performances, while the
recorded variant only model clearly has a noticeably inferior classification performance.
4.2 Obtaining covariate effects from a full data fit
The cross-validation experiments illustrate the substantial gain in prediction accuracy achieved by
the full multilevel model consisting of the effects of individual variants, in addition to the 584 genes
and 96 single base nucleotide substitution meta-features. To gain insights on the effects of these
factors we refitted the (“full”) model on the whole TCGA data set with all 3702 tumors. As before,
we first computed the product design-meta-design matrix XU by counting the total number of
variants corresponding to each meta-feature in a tumor. We then obtained the ranks of the NMI
values with cancer types for all 811,497 variants observed in the data, and screened out all variants
with NMI rank ≥ 250. The group lasso penalty parameter was chosen via a 10-fold cross-validation
(using glmnet). The penalized regression parameter estimates quantifying the variant, gene and
single base nucleotide substitution signature effects were then obtained from the fitted model. To
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aid interpretation, we considered PRAD (prostate cancer) as the reference group, as this group has
tumors with low mutation burden in general, and computed the log odds ratios of being classified
into each of the other six cancer sites (see Remark 3.3). To aid comparison, each log odds ratio
estimate was subsequently multiplied by the associated standard deviation of the predictor and
then exponentiated, providing odds ratios for one standard deviation changes in the predictors.
We first considered the “residual” effects β0 of the raw variants included in the model (retained
after normalized mutual information based screening), i.e., the variant specific effects that are
not explained by the meta-features. Unsurprisingly, most of the estimated residual effects were
zero/small, as a consequence of the group lasso penalty. With PRAD as the reference group, we
computed the corresponding ratio of odds of being classified into one of the other six categories.
In Figure 2, 30 variants with the largest estimated odds ratios are displayed. It appears that the
largest estimated odds ratio is observed in SKCM for BRAF V600E, a mutation that has been
linked to skin cancer in multiple studies (Bailey et al., 2018). It is also of note that a handful of
KRAS variants, such as G12C, G12D, G12R and G12V, have strong non-zero effects on cancer
classification. These findings are in concordance with the existing scientific literature in that we
see the G12C variant exhibiting its largest positive effects in lung adenocarcinoma (LUAD), while
G12D, G12R and G12V display their largest effects on pancreatic cancer (PAAD). These variant
specific effects cannot be captured in a gene-only model that identifies a mutation only through
the associated gene.
Next, to visually assess the relative effects of the genes as meta-features in our cancer classifi-
cation model, we considered the 30 genes with the largest odds ratios of classifying a tumor into
one of the six cancer categories other than PRAD (for one standard deviation changes in the gene
levels), and plotted odds ratios in Figure 3. The figure shows large values for genes whose mutations
are known to be highly tissue specific. For example, mutations at APC have been associated with
colorectal cancer (CODEREAD), those at BRAF and NRAS with melanoma skin cancer (SKCM),
and those at KRAS with both lung (LUAD) and pancreatic (PAAD) cancers.
Finally, to visualize the relative effects of the single base nucleotide substitution signatures in
predicting cancer types, we obtained odds ratios for dominant mutation signature groups. We
considered five dominant signature groups, viz., APOBEC, MMR, POLE, Smoking and UV, each
being a weighted average of the 96 raw single base substitution signatures (Alexandrov et al.,
2013), and computed the corresponding weighted average of the estimated meta-regression coef-
ficients, ω˜h = vh
T ωˆMS−1:96,•, and the weighted design-meta-design matrix, XU•,MS−1:96vh, for
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Figure 2: Treating prostate cancer (PRAD) as the reference category, the (residual) ratio of odds of
classifying a tumor into one of the other six cancer categories, for a one standard deviation change
in the presence/absence of raw variants are plotted for 30 variants with largest (residual) odds
ratios. Each horizontal bar indicates the magnitude of the estimated odds ratios (in a log scale)
associated with the corresponding variant (row) and in each cancer type (column).
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Figure 3: Treating prostate cancer (PRAD) as the reference category, the ratio of odds of classifying
a tumor into one of the other six cancer categories, for a one standard deviation change in the
corresponding level of gene are plotted for 30 genes with largest odds ratios. Each horizontal bar
indicates the magnitude of the odds ratios (in a log scale) for each of the 30 genes (row), and in
each cancer type (column).
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Figure 4: Treating prostate cancer (PRAD) as the reference category, odds ratios of classifying
a tumor into one of the other six cancer categories, for a one standard deviation change in the
corresponding levels of the 5 dominant mutation signature groups are plotted. Each horizontal bar
indicates the magnitude of odds ratio (in a log scale) for each of the 5 dominant mutation signature
groups (rows), and in each cancer type (column).
each of these signature groups where vh denotes the weights associated with the h-th dominant
signature (h ∈ {APOBEC, MMR, POLE, Smoking, UV}). Here ωˆMS−1:96,• (XU•,MS−1:96) is a
sub-matrix of the estimated meta-regression coefficient matrix ωˆ (design-meta-design matrix XU),
with rows (columns) corresponding to the 96 single-base substitution signatures. The weighted ef-
fects ω˜h were then remeasured for one standard deviation changes in these dominant mutation
signatures, by multiplying with standard deviations of the columns of XU•,MS−1:96. Finally, treat-
ing PRAD as the baseline category, the odds ratios for classifying a tumor into one of the other six
categories were computed for one standard deviation changes in these dominant signature groups,
and were plotted in Figure 4. Large odds ratios are obtained for the UV signature in melanoma
skin cancer (SKCM), the smoking signature in lung cancer (LUAD), the MMR signatures in both
colorectal cancer (COADREAD), and the APOBEC signatures in bladder cancer (BLCA), breast
cancer (BRCA), and lung cancer (LUAD). These findings are in perfect alignment with the existing
scientific knowledge (Alexandrov et al., 2013).
5 Discussion
We considered a multi-level multinomial logistic regression model for predicting/classifying primary
sites of origin of tumors with unknown primary. Our model incorporates information on hitherto
unseen mutations through the associated genes and mutation footprints, treated as meta-features
in the model, and uses this information in the classification. We observed substantial gains in
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classification accuracy over approaches that do not take advantage of these meta-features, such as
a recorded variant only classifier, and a gene-level classifier. Along with the variants, we investigated
the roles of the associated genes and the single base nucleotide substitution mutation footprints
as predictors in our model, and gained further insights on the discriminating abilities of these
attributes.
There are a number of future directions in which our current approach and findings could be
extended. First, we limited the scope of our analysis by considering seven common cancer categories
in the TCGA data for classification, using the whole-exome variants as predictors, and using only
gene memberships and single base mutation signatures as meta-features. These were selected for
expository purposes, since these tumor types had adequate sample sizes and well known mutational
features. In a clinical study, interests may lie in a larger number of cancer types with more clinical
relevance, and inclusion of a reference (no cancer) category may be of practical importance, e.g., for
a ctDNA study where the patient may not have cancer at all. It may also be of interest to include
extra-exome variants, obtained for example from a whole genome sequencing study, as predictors to
assess their discriminating/predictive abilities and to see if they improve the performance. Finally,
additional meta features for a variant, such as its replication time, exome size, expression levels
etc. could potentially help extract further information from the rare and unseen variants, thereby
bolstering predictive abilities of the model. Our approach could be easily extended to address
these scientific problems. If the total number of cancer categories is sufficiently large, then a sparse
group lasso penalty (Simon et al., 2013), instead of the group lasso penalty considered in this paper,
could lead to a potentially better classification accuracy. Second, instead of the penalized likelihood
based optimization approach (maximum a posteriori estimation), a full Bayesian approach could
be adopted for estimation of model parameters. Then, instead of predicting the residual effect of a
hitherto unseen variant to be exactly equal to zero, one would consider an ensemble of possible values
via random generation from the associated posterior, as obtained from the meta-regression, and
combine those with posterior samples for residual regression parameters associated with “recorded”
variants, and those for the meta-regression parameters. Note that to properly account for the
sparsity in the predictor space in a full Bayesian framework one would need to use a sparse Bayesian
prior e.g., the spike and slab prior or a global-local shrinkage prior, such as the horseshoe prior
(Carvalho et al., 2009), instead of the lasso type priors considered in this study. Finally, a non-
parametric Bayesian approach to sparse multinomial logistic regression, as considered in Burgette
and Reiter (2013), might also be profitably combined with the hierarchical structure considered in
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this paper. This approach may lead to additional insights such as which mutations and/or meta-
features are effectively “similar” in classifying tumors by appropriately clustering the mutations
into a number of distinct groups.
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